FDA Probes Serious Risk Of Secondary Cancer Following CAR T Cell Therapies
The Food and Drug Administration or FDA said it is investigating serious risk of T-cell malignancies following BCMA or CD19-directed autologous Chimeric Antigen Receptor or CAR T cell Immunotherapies. The … Read More